KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Accured Expenses (2018 - 2025)

Castle Biosciences' Change in Accured Expenses history spans 7 years, with the latest figure at $3.8 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 627.55% year-over-year to $3.8 million; the TTM value through Dec 2025 reached $5.7 million, up 1691.25%, while the annual FY2025 figure was $5.7 million, 1691.25% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $3.8 million at Castle Biosciences, up from $1.4 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.8 million in Q3 2024 and bottomed at -$14.2 million in Q1 2024.
  • The 5-year median for Change in Accured Expenses is $844000.0 (2021), against an average of $347600.0.
  • The largest YoY upside for Change in Accured Expenses was 24500.0% in 2022 against a maximum downside of 1996.06% in 2022.
  • A 5-year view of Change in Accured Expenses shows it stood at -$895000.0 in 2021, then tumbled by 417.54% to -$4.6 million in 2022, then soared by 116.47% to $763000.0 in 2023, then crashed by 195.15% to -$726000.0 in 2024, then skyrocketed by 627.55% to $3.8 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Change in Accured Expenses are $3.8 million (Q4 2025), $1.4 million (Q3 2025), and -$667000.0 (Q2 2025).